Cancer drugs propel growth at AstraZeneca

By the Editorial Team · Tuesday, July 28, 2026

AstraZeneca reported a 6 percent increase in first-half 2026 revenues to nearly £23 billion, led by a 15 percent rise in sales from its oncology division. This growth underscores the critical role of cancer treatments in the company’s portfolio and supports continued investment in research for innovative therapies in oncology and rare diseases.

AstraZeneca reported a solid increase in sales for the first half of 2026, driven primarily by strong demand for its cancer treatments. The pharmaceutical company, headquartered in Cambridge, said total revenues reached nearly £23 billion, representing a 6 percent increase compared with the same period last year at constant exchange rates.

The company’s oncology division was a key contributor to this growth, with revenues rising 15 percent to just under £11 billion. This segment now accounts for almost half of AstraZeneca’s total sales, underscoring the importance of its cancer drug portfolio to the group’s overall performance.

In addition to oncology, AstraZeneca also flagged growth in its rare disease division, which helped support the company’s expanded revenue base. To sustain this momentum, AstraZeneca increased its investment in research and development, emphasizing its commitment to innovation in treatments for patients with complex and unmet medical needs.

AstraZeneca’s performance highlights the ongoing demand for new therapies in oncology and rare diseases, as well as the company’s strategic focus on these areas as key drivers of future growth.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.